International Journal of Hematological Disorders
This proposal aims to discuss various types of hematologic malignancies, eg. Leukemia, lymphoma, myloma, etc. This special issue will concentrate on newer insights pertaining to the pathogenesis of various hematologic cancers, improved diagnostic tools, evaluation of current and future options of treatments as well as discussion on the place of stem cell transplantation in the overall management of patients. In addition, there will be emphasis on the mechanism of action of the novel agents in use and ways to improve them.The aim of the Special Issue is to provide a platform for the researchers to understand the recent advancements and challenges in hematology oncology. These articles will provide an opportunity to the readers to understand and access the scientific information.Scientific subjects will include articles concerning the epigenetic mechanisms of disease/therapy as well as the role of the immune system in hemato-oncology. Very interesting and uncommon subjects will include discussions of extramedullary disease and evaluations of the central nervous system by various imaging techniques. Experts will describe the role of hypomethylating agents in the management of hematologic malignancies and currently emerging and promising investigational therapies. Clinical success relies greatly on supportive therapy, and we will discuss supportive therapy, including infection prophylaxis. Allogeneic hematopoietic stem cell transplantation remains the most effective measure for curing aggressive hematologic malignancies, and a variety of topics will be considered: donor selection, age of recipient, which has been increasing seemingly without limit; therefore, recipient/donor assessments are more important than ever in the aging population. Alternative donor use (e.g., cord blood and haploidentical individuals) has been increasing dramatically; when and who should be considered, what is being investigated? With signi?cant changes occurring with respect to both donors and recipients, the pros and cons of using of anti-thymocyte globulin use in conditioning regimens will be also described.
About the issue
The topics of this special issue include, but are not limited to:
Submission Deadline: December 25, 2014Notification of Acceptance: January 30, 2015Final Version Due: February 25, 2015Special Issue Publishing Date: March 20, 2015
Chief Guest Editor
Iman M. Fawzy, MD, PhDEmail: Clinical.email@example.com
Submit your article now
Manuscripts should be submitted as an attached file to an e-mail directed to the Chief Guest Editor, Iman M. Fawzy at the address: <Clinical.firstname.lastname@example.org>
or through the journal’s Paper Submission System.
After several decades of "stagnation" in the comprehension and management of the various subtypes of plasma cell disorders which are all sharing clonal proliferation of plasma cells with or without excretion of monoclonal proteins came since the late nineties of the past century a new era or "renaissance" in the field of this neoplasm which brought with it a tremendous progression in all areas from basic research and discovery of molecular events underlying the transformation through sophisticated diagnostic and prognostic tools up to an exciting development of first and second generation novel agents which already show benefit in terms of response, disease free survival and even overall survival. This special issue will concentrate on newer insights pertaining to the pathogenesis of plasma cell disorders, improved diagnostic tools, evaluation of current and future options of treatments as well as discussion on the place of stem cell transplantation in the overall management of patients. In addition, there will be emphasis on the mechanism of action of the novel agents in use and ways to improve them.
Submission Deadline: July 15, 2014Notification of Acceptance: August 15, 2014Final Version Due: September 15, 2014Special Issue Publishing Date: October 15, 2014
Yossi CohenAsaf Harofhe University HospitalEmail: email@example.com
Guest EditorOdit Gutwein, MD.Specializations in Internal Medicine and Hematololy, Principal Investigator in Several Phase II and Phase III Clinical Trials
Manuscripts should be submitted as an attached file to an e-mail directed to the Chief Guest Editor, Dr. Yossi Cohen at the address: <firstname.lastname@example.org>